Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas

Fertility and Sterility

Volumn 86, Issue 3, 2006, Pages 719.e15-719.e18

  Knoepfelmacher, Mirta ^a   Danilovic, Debora L S ^a   Rosa Nasser, Rubia H R ^a   Mendonça, Berenice B ^a  

^a Lab Hormonios Genet Molec D   (Brazil)

Author keywords

cabergoline; Gonadotropin secreting pituitary adenoma; spontaneous ovarian hyperstimulation syndrome

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; ESTRADIOL; GONADORELIN; GONADOTROPIN; MEDROXYPROGESTERONE ACETATE;

ABDOMINAL DISTENSION; ADULT; AMENORRHEA; ANAMNESIS; ARTICLE; CASE REPORT; DRUG EFFICACY; ECHOGRAPHY; FEMALE; GALACTORRHEA; HEADACHE; HEMIANOPIA; HUMAN; HYPOPHYSIS ADENOMA; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY HYPERSTIMULATION; OVARY HYPERTROPHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; VISUAL FIELD;

EID: 33748266097     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.01.055     Document Type: Article

References (19)

1. Djerassi A., Coutifaris C., West V.A., Asa S.L., Kapoor S.C., Pavlou S.N., and Snyder P.J. Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation. J Clin Endocrinol Metab 80 (1995) 591-594
2. Christin-Maitre S., Rongieres-Bertrand C., Kottler M.L., Lahlou N., Frydman R., Touraine P., and Bouchard P. A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma. J Clin Endocrinol Metab 83 (1998) 3450-3453
3. Valimaki M.J., Tiitinen A., Alfthan H., Paetau A., Poranen A., Sane T., and Stenman U.H. Ovarian hyperstimulation caused by gonadotroph adenoma secreting follicle-stimulating hormone in 28-year-old woman. J Clin Endocrinol Metab 84 (1999) 4204-4208
4. Tashiro H., Katabuchi H., Ohtake H., Kaku T., Ushio Y., and Okamura H. A follicle-stimulating hormone-secreting gonadotroph adenoma with ovarian enlargement in a 10-year-old girl. Fertil Steril 72 (1999) 158-160
5. Pentz-Vidovic I., Skoric T., Grubisic G., Korsic M., Ivicevic-Bakulic T., Besenski N., Paladino J., Plavsic V., and Zarkovic K. Evolution of clinical symptoms in a young woman with a recurrent gonadotroph adenoma causing ovarian hyperstimulation. Eur J Endocrinol 143 (2000) 607-614
6. Shimon I., Rubinek T., Bar-Hava I., Nass D., Hadani M., Amsterdam A., and Harel G. Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 86 (2001) 3635-3640
7. Castelbaum Aj., Bigdeli H., Post K.D., Freedman M.F., and Snyder P.J. Exacerbation of ovarian hyperstimulation by leuprolide reveals a gonadotroph adenoma. Fertil Steril 78 (2002) 1311-1313
8. Murata Y., Ando H., Nagasaka T., Takahashi I., Saito K., Fukugaki H., Matsuzawa K., and Mizutani S. Succesful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma. J Clin Endocrinol Metab 88 (2003) 1988-1993
9. Vance M.L., Ridgway E.C., and Thorner M.O. Follicle-stimulanting hormone and alpha-subunit-secreting pituitary tumor treated with bromocriptine. J Clin Endocrinol Metab 61 (1985) 580-584
10. Berezin M., Olchovsky D., Pines A., Tadmor R., and Lunenfeld B. Reduction of follicle-stimulating hormone (FSH) secretion in FSH-producing pituitary adenoma by bromocriptine. J Clin Endocrinol Metab 59 (1984) 1220-1223
11. Yamakita N., Komaki T., Murai T., and Kawamura S. Reduction of plasma gonadotropin levels and pituitary tumor size by treatment with bromocriptine in a patient with gonadotropinoma. Intern Med 38 (1999) 266-271
12. Abs R., Parizel P.M., and Beckers A. Acute effects of parlodel-LAR and responses to long term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma. J Endocrinol Invest 14 (1991) 135-138
13. Colao A., Ferone D., Lastoria S., Cerbone G., Di Sarno A., Di Somma C., Lucci R., and Lombardi G. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically nonfunctioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clin Endocrinol (Oxf) 52 (2000) 437-445
14. Kwekkeboom D.J., and Lamberts S.W.J. Long-term treatment with dopamine agonist CV 205-502 of patients with a clinically nonfunctioning, gonadotroph, or α-subunit secreting pituitary adenoma. Clin Endocrinol (Oxf) 36 (1992) 171-176
15. Lesse G., Jeffreys R., and Vora J. Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone. Postgrad Med J 73 (1997) 507-508
16. Lamberts S.W. Bromocriptine increasingly suppresses the in vitro gonadotropin and alpha-subunit release from pituitary adenomas during long term culture. J Clin Endocrinol Metab 71 (1990) 718-724
17. Stefaneanu L., Kovacs K., Horvath E., Buchfelder M., Fahlbusch R., and Lancranjan L. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrinology 14 (2001) 329-336
18. Lohmann T., Trantakis C., Bieold M., Prothmann S., Guenzel S., Schober R., and Paschke R. Minor tumor shrinkage in non functioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary 4 (2001) 173-178
19. Pivonello R., Matrone C., Filppela M., Cavallo L.M., Somma C.D., Cappabianca P., Colao A., Annunziato L., and lombardi G. Dopamine receptor expression and function in clinically nonfuctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 89 (2004) 1674-1683